Literature DB >> 8328562

Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?

M Maes1, E Bosmans, H Y Meltzer, S Scharpé, E Suy.   

Abstract

OBJECTIVE: There is extensive evidence that major depression, and particularly melancholia, is characterized by hypothalamic-pituitary-adrenal (HPA) axis hyperactivity as well as systemic immune activation, which may be accompanied by increased interleukin-1 beta production. Interleukin-1 beta is known to enhance HPA axis activity during an immune response. This study investigated whether interleukin-1 beta production is related to HPA axis activity in depressed subjects.
METHOD: The subjects were 28 inpatients with major or minor depression and 10 normal comparison subjects. The authors measured 1) the subjects' cortisol levels after an overnight 1-mg dexamethasone suppression test (DST) and 2) mitogen-stimulated supernatant interleukin-1 beta production by peripheral blood mononuclear cells.
RESULTS: Statistically significant positive correlations between interleukin-1 beta production and post-DST cortisol values were found in the study group as a whole and in the depressed and normal subgroups separately.
CONCLUSIONS: It is suggested that constituents of the immune response (such as interleukin-1 beta) in major depression may contribute to HPA axis hyperfunction in that illness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328562     DOI: 10.1176/ajp.150.8.1189

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  65 in total

1.  Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response.

Authors:  M Maes; R Verkerk; E Vandoolaeghe; F Van Hunsel; H Neels; A Wauters; P Demedts; S Scharpé
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

3.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

Review 4.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 5.  Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.

Authors:  Thaddeus W W Pace; Fang Hu; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2006-10-27       Impact factor: 7.217

Review 6.  Role of interleukin-1 in stress responses. A putative neurotransmitter.

Authors:  F Shintani; T Nakaki; S Kanba; R Kato; M Asai
Journal:  Mol Neurobiol       Date:  1995-02       Impact factor: 5.590

Review 7.  Cytokines and glucocorticoid receptor signaling. Relevance to major depression.

Authors:  Thaddeus W W Pace; Andrew H Miller
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 8.  Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis.

Authors:  A Masi; D S Quintana; N Glozier; A R Lloyd; I B Hickie; A J Guastella
Journal:  Mol Psychiatry       Date:  2014-06-17       Impact factor: 15.992

Review 9.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.

Authors:  Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

Review 10.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.